

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**  
**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Anyone with a prostate can develop benign prostatic hyperplasia, including people who have proposed, started or completed male to female gender reassignment.
---

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

Documentation should refer to people rather than to men.
--

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No – the draft scope already refers to ‘people’, where this is appropriate.
---

- |  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

No.
-----

**Approved by Associate Director (name):** Helen Knight

**Date:** 17 August 2012